Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.16), $0.16 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $144.84 million versus the consensus estimate of $141.21 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2024 revenue of $645-675 million, versus the consensus of $661.7 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.